LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...

(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...

UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...

For investors searching for shares to buy in February, this small UK firm might be worth considering for inclusion in a ...

VIVO, a fast-growing early-stage German contract research organization (CRO) has acquired two clinical research units from Clinical Research Services (CRS), in Mannheim and Kiel, Germany, for a total ...

(Alliance News) - hVIVO PLC on Wednesday released an optimistic pre-annual results trading update, and said it expects "further strong growth" next year. However, the stock was down 7.4% at 18.89 ...

Hvivo paid £10 million in cash for the takeover of CRS, a German clinical trial firm with two research units, marking the ...

Clinical trials company Hvivo has completed its first acquisition, buying two research units from German group CRS for €10 ...

LONDON - hVIVO plc, a leading early-stage Contract Research Organisation (CRO) known for its human challenge clinical trials, has acquired two Clinical Research Units (CRUs) from CRS Clinical Research ...

Pharmaceutical services firm hVivo, formerly Open Orphan, has acquired two clinical trial units in Germany from CRS Clinical ...

The UK Health Security Agency has finally provided an update following a surge of HMPV, formerly called the "mystery" virus, ...